Finding a needle in a haystack: The hidden costs of asymptomatic testing in a low incidence setting

Vinay Srinivasan MPH1, Shruti K. Gohil MD3, Shira R. Abeles MD2, Deborah S. Yokoe MD4, Stuart H. Cohen MD5, Lynn Ramirez-Avila MD6, Kavitha K. Prabaker MD7 and Annabelle M. de St. Maurice MD8

1David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, 2Division of Infectious Diseases, Department of Medicine, University of California San Diego School of Medicine, San Diego, California, 3Division of Infectious Diseases, Department of Medicine, University of California Irvine, Irvine, California, 4Division of Infectious Diseases, Department of Medicine, University of California San Francisco, San Francisco, California, 5Division of Infectious Diseases, Department of Medicine, University of California Davis, Sacramento, California, 6Division of Pediatric Infectious Diseases and Global Health, Department of Pediatrics, University of California San Francisco, San Francisco, California, 7Division of Infectious Diseases, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California and 8Division of Infectious Diseases, Department of Pediatrics, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California

To the Editor—Early in the coronavirus disease 2019 (COVID-19) pandemic, when testing was limited and the prevalence of severe acute respiratory coronavirus virus 2 (SARS-CoV-2) was unknown, public health recommendations restricted testing for individuals at high risk for COVID-19. Risk factors included travel history, symptoms, and close contact with someone who had a history of COVID-19. As access to testing expanded and concerns for asymptomatic transmission mounted, healthcare facilities broadened COVID-19 surveillance strategies to include testing for all asymptomatic patients requiring hospital admission or aerosol-generating procedures.

Simultaneously, national and global PPE shortages amplified concerns about high risks for to healthcare providers (HCPs). Initial studies reported infection from patients as the primary mode of transmission in up to 60% of COVID-19 infections in healthcare workers before the pandemic was recognized.1 Since that time, significant advances in testing capacity and PPE availability have been made, coupled with reassurance about the protective effects of PPE.2 Rates of COVID-19 positivity among asymptomatic patients presenting for surgery have been low throughout the pandemic: only 0.13% at an academic facility centered in one of the counties with the highest COVID-19 prevalence nationally. The total number of tests collected for asymptomatic surgical patients has exceeded 100,000 in the past 12 months.3,4 Data collected during this pandemic have demonstrated that healthcare workers are unlikely to become infected with COVID-19 when wearing appropriate PPE.2 Even in situations in which healthcare providers were performing an aerosol-generating procedure on a COVID-19–positive patient, the risk among those wearing a surgical mask and a respirator was equivalent.5 As PPE supply has increased in the United States, many healthcare institutions have begun using respirators and eye protection for all aerosol-generating procedures regardless of a patient’s SARS-CoV-2 status, further decreasing the risk of unanticipated SARS-CoV-2 transmission.

Furthermore, as the incidence of a disease declines, the positive predictive value (PPV) of a test for that disease necessarily drops, even for tests with a high sensitivity and specificity. At low prevalence, the positive predictive value (PPV) of a given test is expected to be more sensitive to changes in underlying rates of disease. To illustrate this, we modeled the relationship between 7-day cumulative incidence of COVID-19 in the community (x-axis) and PPV (y-axis) for a PCR test with similar performance characteristics to those used at UCLA Health (ie, 96% sensitivity and 99% specificity), assuming a weekly testing strategy (Fig. 1). We show that false positives exceed the number of true positives when 7-day cumulative COVID-19 incidence is below 1,030 cases per 100,000 persons. These false positives can delay care, can cause unnecessary hospital and community-setting quarantines, and can lead to repeated retesting. In addition, direct and indirect costs accrue with testing asymptomatic individuals at low risk of having COVID-19. First, COVID-19 assays require expensive machines, reagents, and technologists’ labor. According to a recent Kaiser Family Foundation survey of 93 hospitals, the median cost of a COVID-19 test was $148.8 Additional labor and supply expenses are incurred by clinics and hospitals running COVID-19 testing sites for preoperative patients.

The highest 7-day average of COVID-19 cases in the United States was 533 of 100,000 in January 2020; however, rates varied substantially by locality. Currently, the 7-day average incidence is 13.65 of 100,000 in Los Angeles County and 48.95 of 100,000 nationally,7 with continued steady declines every day, suggesting that at this juncture in the US COVID-19 pandemic, the risk of false-positive tests and their associated consequences far outweigh the benefits of mass COVID-19 testing. The justification for maintaining such time and resource-intensive surveillance programs becomes more complex in the context of widespread use of highly effective vaccines in healthcare providers. It is time to rethink the strategy of testing asymptomatic individuals entering hospitals or receiving procedures.

Author for correspondence: Annabelle de St. Maurice, Email: adestmaurice@mednet.ucla.edu

Cite this article: Srinivasan V, et al. (2021). Finding a needle in a haystack: The hidden costs of asymptomatic testing in a low incidence setting. Infection Control & Hospital Epidemiology. https://doi.org/10.1017/ice.2021.288

© The Author(s), 2021. Published by Cambridge University Press on behalf of The Society for Healthcare Epidemiology of America.
Acknowledgments.

Financial support. No financial support was provided relevant to this article.

Conflicts of interest. All authors report no conflicts of interest relevant to this article.

References


Fig. 1. Relationship between the positive predictive value (PPV) of COVID-19 tests and the 7-day COVID-19 cumulative incidence (cases per 100,000 persons). The blue line represents the PPV of a COVID-19 PCR test as the 7-day cumulative incidence of COVID-19 changes in a community, assuming a sensitivity of 96% and specificity of 99%. The dashed line represents the point at which the PPV is 50%.